Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 11 of 11 results for mepolizumab

  1. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  2. Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)

    NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA846

  3. Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) (TA845)

    NICE is unable to make a recommendation on mepolizumab (Nucala) for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA845

  4. Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)

    NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA847

  5. Mepolizumab for treating chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

  6. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  7. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  8. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

  9. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

  10. SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 09 July 2024

  11. Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.